---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-038131"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:12:00.097965+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q1 revenue down 5% to $13.0M; GAAP EPS loss $(0.37), non-GAAP loss $(0.09)

## Summary
- Total revenue $13.0M, down 5% from $13.7M a year ago; gross profit $7.4M (-8% YoY).
- GAAP net loss $(6.4)M or $(0.37) per share vs. $(3.8)M or $(0.21) last year.
- Non-GAAP net loss $(1.6)M or $(0.09) per share vs. $(0.1)M or $(0.01) last year.
- Reaffirms FY2023 guidance: net revenue growth at least 10% YoY, gross margins 58-62%.
- Rolling 12-month net revenue retention fell to 86% from 124%; avg revenue per top 20 pharma co. down to ~$1.99M.

## SEC filing metadata
- accession: 0001213900-23-038131
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390023038131/0001213900-23-038131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390023038131/ea178286-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-038131
- JSON: https://secwatch.observer/filing/0001213900-23-038131.json
- Plain text: https://secwatch.observer/filing/0001213900-23-038131.txt

## Key facts
- Earnings Releases
  OptimizeRx Corp reported the three months ended March 31, 2023 results: revenue $13.0 million, net income $(6.4) million, EPS $(0.37). Guidance reaffirmed.
  - Period: the three months ended March 31, 2023
  - Revenue: $13.0 million
  - Net income: $(6.4) million
  - EPS: $(0.37)
  - Guidance: reaffirmed
  - Result: reported results
  source text: Financial Highlights ● Revenue in the first quarter of 2023 decreased 5% to $13.0 million, as compared to $13.7 million in the same year ago period. ● Gross profit in the first quarter of 2023 decreased 8% year-over-year to $7.4 million, from $8.1 million during the first quarter of 2022. ● GAAP net loss totaled $(6.4) million or $(0.37) per basic and diluted shares outstanding
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390023038131/0001213900-23-038131-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.